WEI Yan, HONG Yu-zhi, YE Xun
Department of Endocrinology, Traditional Chinese Medicine Hospital of Hangzhou, Hangzhou (310007), China.
Chin J Integr Med. 2008 Dec;14(4):298-302. doi: 10.1007/s11655-008-0298-7. Epub 2008 Dec 12.
To observe the therapeutic effect of Tang No.1 granule (1, T1G) in treating patients with impaired glucose tolerance (IGT).
One hundred and forty patients with IGT and with Pi-Wei dampness-heat syndrome type were assigned randomly according to their visiting sequence into two equal groups. The control group received only general knowledge about IGT, but to the treated group, based on current knowledge available, T1G was given additionally for 6 months. Changes in related laboratory indexes, including fasting plasma glucose and insulin (FPG and FINS), plasma glucose 2 h after meal (2hPG), glycosylated hemoglobin (HbA1c), serum triglyceride (TG), low density lipoprotein cholesterol (LDL) and insulin resistance index (HOMA-IR), were observed.
The levels of FPG, 2hPG, HbA1c, FINS, TG and HOMA-IR were significantly decreased after treatment in the treated group, showing a significant difference compared to the control group (P<0.01). Among them, HbA1c decreased from 7.08+or-1.41% to 6.56+or-1.29% in the treated group, while in the control group, it decreased from 7.02+or-1.37% to 6.93+or-1.31%. The level of LDL was also reduced in the treated group after treatment (P<0.05). In the treated group, 13 out of 68 patients (19.12%) had their glucose tolerance reversed to normal, while in the control group, only 2/64 (3.1%) got it reverse; a comparison between the two groups in terms of reversion rate showed a significant difference (P<0.01). No severe adverse reaction was found in the therapeutic course.
T1G has good clinical effect as a treatment intervention for IGT, as it could improve glycometabolism, significantly depress the levels of post-prandial blood sugar and blood lipids, alleviate clinical symptoms of patients, and effectively cut-off and reverse the yielding and development of diabetes mellitus.
观察糖1号颗粒(T1G)治疗糖耐量减低(IGT)患者的疗效。
将140例IGT且属脾胃湿热证型的患者按就诊顺序随机分为两组,每组各70例。对照组仅给予IGT相关常识,治疗组在现有知识基础上额外给予T1G治疗6个月。观察相关实验室指标的变化,包括空腹血糖和胰岛素(FPG和FINS)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、血清甘油三酯(TG)、低密度脂蛋白胆固醇(LDL)及胰岛素抵抗指数(HOMA-IR)。
治疗组治疗后FPG、2hPG、HbA1c、FINS、TG及HOMA-IR水平均显著下降,与对照组比较差异有统计学意义(P<0.01)。其中,治疗组HbA1c由7.08±1.41%降至6.56±1.29%,对照组由7.02±1.37%降至6.93±1.31%。治疗组治疗后LDL水平也降低(P<0.05)。治疗组68例患者中有13例(19.12%)糖耐量恢复正常,对照组64例中仅2例(3.1%)恢复正常;两组恢复率比较差异有统计学意义(P<0.01)。治疗过程中未发现严重不良反应。
T1G作为IGT的治疗干预措施具有良好的临床效果,可改善糖代谢,显著降低餐后血糖及血脂水平,缓解患者临床症状,有效阻断并逆转糖尿病的发生发展。